Answers for the psychedelic-curious

Which psychedelic is right for me?

No web page can answer this for you, and anyone who answers it confidently is guessing. What is true: these medicines differ in length, intensity, legal access and how much research stands behind them. Those differences narrow the field a long way. The last step is a conversation with someone who knows your history.

By Troy Allen, Founder, Guides Collective Last updated: October 21, 2026

This is the most common question people arrive with, and it is usually the wrong first question — not because it is naive, but because it puts the molecule before the person. Nobody can responsibly tell you which substance suits you without knowing your medical history, your medications, your mental-health history, where you live, and what kind of support you will have afterwards.

What a page like this can do is show you the real differences, so that by the time you talk to a practitioner you are asking sharper questions.

You are in the majority if you don't know yet. Of the 237 people who answered the medicine-preference question on our intake, 216 — 91% — said they were open to all options rather than arriving set on one. Only 21 restricted themselves to regulated options. Being undecided is the normal starting position, not a gap in your research.

The six options, side by side

Read the legal column first. For most people in most U.S. states, legality removes more options than preference does.

Medicine	Typical session length	Character	U.S. legal status (Oct 2026)	Research stage
Psilocybin	4–6 hours, plus preparation and integration sessions	Perceptual and emotional; widely described as inward and hard to predict in advance	Schedule I federally. Supported legal access exists only through Oregon's licensed service centers, Colorado's licensed healing centers, or a clinical trial. Several cities have deprioritised possession enforcement, which is not the same as legal access.	Two Phase 3 trials in treatment-resistant depression met their primary endpoints (COMP005, COMP006). The sponsor has a rolling FDA submission underway and expects to complete it in Q4 2026; approval would also require DEA rescheduling. Not approved. (What the trials show)
MDMA	6–8 hours alongside a therapy protocol	Emotionally open with little perceptual distortion; studied as an adjunct to talk therapy rather than on its own	Schedule I. Access only through a clinical trial or expanded access.	The FDA declined the PTSD application in August 2024. A resubmission without a new Phase 3 trial was reported in August 2026 but has not been publicly confirmed by the FDA. Not approved. (What the trials show)
Ketamine / esketamine	40–60 minutes for an infusion; roughly two monitored hours for esketamine	Dissociative rather than classically psychedelic; usually given as a series of sessions	Schedule III and legally prescribable. Esketamine (Spravato) is FDA-approved for treatment-resistant depression and dispensed under a restricted-distribution (REMS) programme; generic ketamine is used off-label in clinics nationwide.	Approved for treatment-resistant depression as esketamine. Effects arrive quickly and generally require repeat dosing to hold.
LSD	8–12 hours	The longest of the classic psychedelics, which makes the setting and the support around it matter more, not less	Schedule I. Clinical trials only.	Phase 2b results in generalized anxiety disorder were published in JAMA. The sponsor has announced positive topline results from two Phase 3 anxiety trials (August and September 2026); no application has been approved. Not approved. (What the trials show)
Ayahuasca / DMT	A ceremony typically runs 4–6 hours; vaporised DMT lasts minutes	Ceremonial and physically demanding — nausea and vomiting are an expected part of ayahuasca, not a complication	DMT is Schedule I. Narrow federal religious exemptions cover specific congregations only (the UDV, and some Santo Daime churches); they do not extend to the public.	Small pilot trials in treatment-resistant depression. Not approved.
Microdosing	Not a session — sub-perceptual amounts taken on a schedule	By design you are not meant to feel much; there is no journey to be guided through	Follows the parent substance, so psilocybin and LSD microdosing are federally illegal	Placebo-controlled trials have largely failed to separate microdosing from placebo. Treat strong claims here with more suspicion than usual.

What actually narrows the choice

In practice, four constraints do most of the work — and none of them is "which one sounds most appealing."

1. What is legally available where you live

If you want supported, above-ground access in the United States today, the honest list is short: ketamine through a licensed medical provider, psilocybin through Oregon's or Colorado's regulated programmes, or a clinical trial. Everything else either requires travel or sits outside the law. That single fact eliminates most of the table for most people.

2. Your medications and medical history

This is the constraint people most often underestimate. Of the 281 people who completed our intake, 55 — one in five — told us they were currently taking medication. Antidepressants, mood stabilisers, cardiac medication and a personal or family history of bipolar disorder or psychosis all change the picture, and some of them change it to "not this, and not now." Twenty-six people who completed our intake named bipolar disorder; that is a conversation with a prescriber, not a question to settle by reading.

3. How long a session you can actually hold

An eight-to-twelve-hour LSD session and a forty-minute ketamine infusion are not variations on a theme. They demand different amounts of time, different childcare arrangements, different recovery days, and different amounts of trust in whoever is sitting with you.

4. Who supports you in the weeks afterwards

Integration is the part people skip and then regret skipping. Of 239 completed preference records, 71 people — about 30% — told us they were not yet sure what format they wanted at all. That uncertainty is worth taking to a consultation rather than resolving by guessing.

Why the fit is with the person, not the molecule

Two people can take the same substance in the same amount and have experiences with nothing in common. What reliably differs is who prepared them, who was in the room, and who helped them make sense of it afterwards. That is the part you can actually choose well — and it is the part the research keeps pointing at when it talks about "set and setting."

So the practical sequence is: find a practitioner you trust, bring your history and your constraints, and let the choice of medicine fall out of that conversation. Not the reverse.

Reading next: how to choose a psychedelic — the questions to bring to a consultation, and how to tell whether a guide is legitimate.

Where our numbers come from

Figures attributed to Guides Collective on this page come from our own intake questionnaire, completed by 281 adults between 23 December 2025 and 1 August 2026. They describe the people who came to us, not the general population, and they are self-reported. We publish them because nobody else in this category publishes anything comparable — not because they settle a clinical question.

You don't have to decide alone

Tell us what you're working with and we'll show you the guides we'd choose for your situation. The medicine is a conversation you have with them — not a box you tick first.

Start the free 5-minute questionnaire

Private · No commitment · No experience needed

Frequently asked questions

Which psychedelic is best for a beginner?+

There is no consensus answer, and treating one as "the beginner option" is misleading. What matters far more for a first experience is a legal route, a proper medical and psychiatric screening, a shorter rather than longer session, and a trained person present. Any of those decisions can make a gentle medicine difficult and a strong one manageable.

Can I choose a psychedelic based on my diagnosis?+

Not directly. Depression has by far the most research behind it, and esketamine is the only FDA-approved option in that space. For every other combination of substance and condition, the evidence is either early or absent. A diagnosis narrows the conversation; it does not select a substance.

What if I'm on antidepressants?+

That has to be worked out with the prescriber who manages your medication, before anything else. Some combinations carry real interaction risk, some blunt the experience, and stopping a psychiatric medication to make a psychedelic "work better" is its own hazard. One in five people who complete our intake is currently on medication, so this is an ordinary situation, not a disqualifying one — but it is a clinical question.

Is there any legal way to do this in the United States?+

Yes, three of them. Ketamine is prescribable and available through licensed clinics nationwide, including FDA-approved esketamine for treatment-resistant depression. Psilocybin is legally available through Oregon's licensed service centers and Colorado's licensed healing centers. And clinical trials recruit continuously. Local decriminalisation is not the same as legal access.

How does Guides Collective decide what to suggest?+

We don't suggest a substance. You complete an intake describing your situation, constraints and preferences, and we show you the vetted guides whose focus areas and format match — usually a small number chosen for you rather than a directory to sort through. What happens in a session is between you and that guide.

Sources

About this page

Guides Collective is an informational platform that helps adults explore profiles of independent psychedelic guides. It is not a medical or mental-health provider and does not provide therapy, medical care, or psychedelic services.

All guides operate independently and are not employees, contractors, or agents of Guides Collective. Guides Collective does not verify guide-provided descriptions or credentials, does not recommend, endorse, or supervise any guide or service, and does not oversee or participate in any services guides offer.

Guides Collective does not provide or facilitate access to any substances. Each guide is solely responsible for their own services, communications, and compliance with local laws. Users are responsible for evaluating whether a guide's experience and approach are appropriate for their situation. No specific outcomes are promised or guaranteed.

Nothing on this page recommends, prescribes, or endorses the use of any substance for any condition, and nothing here is a substitute for care from a qualified clinician. Educational information is provided for context only and does not constitute medical, legal, or therapeutic advice. Research and legal information reflect publicly available sources as of the last-updated date above and may change; consult a qualified attorney or clinician about your specific situation. If you are in crisis, call or text 988 (U.S.).